Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM

Diabetologia

Volumn 39, Issue 12, 1996, Pages 1546-1553

  Nauck, M A ^a   Wollschlager D ^b   Werner, J ^b   Holst, J J ^c   Orskov C ^c   Creutzfeldt, W ^d   Willms, B ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Fachklinik Diabet S   (Germany)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

GLP 1 7 36 amide ; glucagon; incretin; insulin; pharmacokinetics

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; INSULIN;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; HUMAN; HYPERGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; BLOOD GLUCOSE; C-PEPTIDE; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GASTRIC EMPTYING; GASTROINTESTINAL HORMONES; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDES;

EID: 0029907680     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050613     Document Type: Conference Paper

References (33)

1. Ørskov C (1992) Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 35: 701-711
2. Creutzfeldt W, Nauck M (1992) Gut hormones and diabetes mellitus. Diabetes Metab Rev 8: 149-177
3. Kreymann B, Ghatei MA, Williams G, Bloom SR (1987) Glucagon-like peptide 1 7-36: a physiological incretin in man. Lancet II:1300-1304
4. Nauck M, Bartels E, Ørskov C, Ebert R, Creutzfeldt W (1993) Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7-36 amide] infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76: 912-917
5. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 (GLP-1) [7-36 amide] but not of synthetic human gastric inhibitory polypeptide (GIP) in patients with NIDDM. J Clin Invest 91: 301-307
6. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF (1992) Insulinotropic action of glucagon-like peptide-I-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15: 270-276
7. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 [7-36 amide] in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 741-744
8. Weir GC, Mojsov S, Hendrick GK, Habener JF (1989) Glucagon-like peptide I (7-37) actions on endocrine pancreas. Diabetes 38: 338-342
9. Ørskov C, Wetlergren A, Holst JJ (1993) Biological effects and metabolic rates of glucagonlike peptide-1 7-36amide and glucagon-like peptide -1 7-37 in healthy subjects are indistinguishable. Diabetes 42: 658-661
10. Weber I, Bach-Esser A-K, Bach I et al. (1995) Prolonged normalization of fasting hyperglycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in NIDDM patients. Diabetologia 38[Suppl 1]:A171 (Abstract)
11. Gutniak M, Ørskov C, Holst JJ, Ahren B, Efendic S (1992) Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes. N Engl J Med 326: 1316-1322
12. Gutniak MK, Linde B, Holst JJ, Efendic S (1994) Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycaemia in NIDDM. Diabetes Care 17: 1039-1044
13. Ritzel R, Ørskov C, Holst JJ, Nauck MA (1995) Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response relationships. Diabetologia 38: 720-725
14. Nauck MA, Wollschläger D, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Willms B (1995) Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 38[Suppl 1]:A39 (Abstract)
15. Willms B, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Nauck MA (1996) Gastric emptying, glucose responses and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide 1 (GLP-1) [7-36 amide] in type 2 (non-insulin-dependent) diabetic patients. J Clin Endocrinol Metab 81: 327-332
16. Kalorien mundgerecht. 9th edition. Umschau-Verlag, Frankfurt 1993
17. George JD (1968) New clinical method for measuring the rate of gastric emptying; the double sampling test meal. Gut 9: 237-242
18. Hurwitz A (1981) Measuring gastric volume by dilution. Gut 22: 85-93
19. Ørskov C, Holst JJ (1987) Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand J Clin Lab Invest 47: 165-174
20. Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes 43: 535-539
21. Holst JJ (1982) Evidence that peak II GLI or enteroglucagon is identical to the C-terminal sequence (residues 33-69) of glicentin. Biochem J 207: 381-388
22. Krarup T, Madsbad S, Moody AJ, Regeur L, Faber OK, Holst JJ, Sestoft L (1983) Diminished gastric inhibitory polypeptide (GIP) response to a meal in newly diagnosed type 1 (insulin dependent) diabetics. J Clin Endocrinol Metab 56: 1306-1312
23. Holman RR, Turner RC (1977) Diabetes: the quest for basal normoglycaemia. Lancet I:469-474
24. Holman RR, Turner RC (1980) The basal plasma glucose: a simple relevant index of maturity-onset diabetes. Clin Endocrinol 14: 279-286
25. Mentlein R, Gallwitz B, Schmidt WE (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214: 829-835
26. Deacon CF, Johnsen AH, Holst JJ (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80: 952-957
27. Deacon CF, Nauck MA, Nielsen M, Pridal L, Willms B, Holst JJ (1995) Both subcutaneously and intravenously administered glucagon-like peptide-1 are rapidly degraded from the amino terminus in type II diabetic patients and in healthy subjects. Diabetes 44: 1126-1131
28. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ (1993) Truncated GLP-1 (proglucagon 87-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38: 665-673
29. Nauck MA, Ettler R, Niedereichholz U, Ørskov C, Holst JJ, Schmiegel W (1995) Inhibition of gastric emptying by GLP-1 [7-36 amide] or [7-37]: effects on postprandial glycaemia and insulin secretion. Gut 37[Suppl 2]:A124 (Abstract)
30. Qualmann C, Nauck MA, Holst JJ, Ørskov C, Creutzfeldt W (1995) Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetol 32: 13-16
31. Fehmann HC, Göke R, Göke B, Bachle R, Wagner B, Arnold R (1991) Priming effect of glucagon-like peptide-1 (7-36) amide, glucose-dependent insulinotropic polypeptide and cholecystokinin-8 at the isolated perfused rat pancreas. Biochim Biophys Acta 1091: 356-363
32. Fehmann HC, Habener JC (1991) Homologous desensitization of the insulinotropic glucagon-like peptide-I (7-37) receptor on insulinoma (HIT-T15) cells. Endocrinology 128: 2880-2888
33. Hargrove DM, Nardone NA, Persson LM, Parker JC, Stevenson RW (1995) Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration. Metabolism 44: 1231-1237